From the *Emory University School of Medicine; †Epidemiology Branch, ‡Quantitative Sciences and Informatics Branch, Division of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention; §Northrop Grumman Inc., Atlanta, GA; ¶Pediatric Adolescent Maternal AIDS Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Rockville, MD; ‖Baylor College of Medicine, Houston, TX; and **University of South Florida School of Medicine, Tampa, FL.
Pediatr Infect Dis J. 2013 Oct;32(10):1089-95. doi: 10.1097/INF.0b013e31829ee893.
Little is known about immune reconstitution inflammatory syndrome in children in the United States.
LEGACY is a longitudinal cohort study of HIV-infected participants 0-24 years at enrollment during 2005 to 2007 from 22 US clinics. For this analysis, we included participants with complete medical record abstraction from birth or time of HIV diagnosis through 2006. Opportunistic illness (OI) included AIDS-defining conditions and selected HIV-related diagnoses. We calculated the incidence (#/100 patient-years) of OI diagnosed in the months pre- and postinitiation of the first highly active antiretroviral therapy (HAART) regimen which was followed by ≥1 log reduction in HIV viral load. We defined OI as immune reconstitution inflammatory syndrome if an OI incidence increased after HAART initiation. "Responders" were defined as experiencing ≥1 log decline in viral load within 6 months after HAART initiation.
Among 575 patients with complete chart abstraction, 524 received HAART. Of these 524 patients, 343 were responders, 181 were nonresponders and 86 experienced OI. Responders accounted for 98 of 124 (79%) of OI. Pre-HAART and post-HAART OI incidences were 43.7 and 24.4 (P = 0.003), respectively, among responders and 15.9 and 9.1 (P = 0.2), respectively, among nonresponders. Overall, OI incidences among responders and nonresponders were 33.8 and 12.3, respectively (P = 0.002). Responders were more likely than nonresponders to experience herpes simplex and herpes zoster before HAART initiation (all, P < 0.002).
The lack of immune reconstitution inflammatory syndrome in participants initiating HAART may be due to low overall OI rates. The unexpectedly higher OI prevalence comprised mainly of herpes simplex and zoster, before HAART initiation among responders, may have motivated them to better adhere to HAART.
在美国,人们对儿童中的免疫重建炎症综合征知之甚少。
LEGACY 是一项针对 HIV 感染者的纵向队列研究,研究对象为 2005 年至 2007 年间在 22 个美国诊所入组时年龄为 0-24 岁的 HIV 感染者。在此分析中,我们纳入了自出生或 HIV 诊断时起至 2006 年完整病历记录可查的参与者。机会性感染(OI)包括艾滋病定义性疾病和某些 HIV 相关诊断。我们计算了在开始首次高效抗逆转录病毒治疗(HAART)方案前和方案后(HIV 病毒载量降低≥1 对数)的几个月中诊断出的 OI 的发病率(每 100 患者年发病数)。如果在开始 HAART 后 OI 发病率增加,则将 OI 定义为免疫重建炎症综合征。将在 HAART 开始后 6 个月内 HIV 病毒载量下降≥1 对数的患者定义为“应答者”。
在 575 例完整病历记录可查的患者中,524 例接受了 HAART。在这 524 例患者中,343 例为应答者,181 例为无应答者,86 例发生了 OI。应答者占 124 例 OI 患者中的 98 例(79%)。应答者的 HAART 前和 HAART 后 OI 发病率分别为 43.7 和 24.4(P = 0.003),无应答者的发病率分别为 15.9 和 9.1(P = 0.2)。总体而言,应答者和无应答者的 OI 发病率分别为 33.8 和 12.3(P = 0.002)。在开始 HAART 前,应答者比无应答者更有可能发生单纯疱疹和带状疱疹(均 P<0.002)。
开始 HAART 的参与者中缺乏免疫重建炎症综合征可能是由于整体 OI 发生率较低所致。令人意外的是,在 HAART 开始前,应答者中以单纯疱疹和带状疱疹为主的更高 OI 发生率可能促使他们更好地坚持 HAART。